Cognition Therapeutics Stock Performance
| CGTX Stock | USD 0.45 0.01 2.17% |
On a scale of 0 to 100, Cognition Therapeutics holds a performance score of 4. The firm shows a Beta (market volatility) of 0.87, which signifies possible diversification benefits within a given portfolio. Cognition Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Cognition Therapeutics is expected to follow. Please check Cognition Therapeutics' total risk alpha, as well as the relationship between the downside variance and daily balance of power , to make a quick decision on whether Cognition Therapeutics' price patterns will revert.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Cognition Therapeutics are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, Cognition Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Acquisition by John Doyle of 109824 shares of Cognition Therapeutics subject to Rule 16b-3 | 11/29/2024 |
2 | Cognition Therapeutics Is Targeting A Critical Form Of Dementia | 01/10/2025 |
3 | Acquisition by Fletcher Aaron G.l. of 500095 shares of Cognition Therapeutics at 1.05 subject to Rule 16b-3 | 01/23/2025 |
4 | Cognition Therapeutics Rating Increased to Strong-Buy at Brookline Capital Management | 01/28/2025 |
5 | Cognitions Positive Phase 2 SHIMMER Study of Zervimesine in Dementia with Lewy ... | 01/30/2025 |
6 | Acquisition by Lisa Ricciardi of 38851 shares of Cognition Therapeutics at 0.7722 subject to Rule 16b-3 | 01/31/2025 |
7 | Disposition of 28960 shares by Lisa Ricciardi of Cognition Therapeutics at 0.666 subject to Rule 16b-3 | 02/03/2025 |
8 | Acquisition by Lisa Ricciardi of 631300 shares of Cognition Therapeutics subject to Rule 16b-3 | 02/04/2025 |
9 | Cognition Therapeutics Presents Phase 2 Results For Drug To Fight DLB At International Conference | 02/05/2025 |
10 | Disposition of 1723 shares by John Doyle of Cognition Therapeutics at 0.5901 subject to Rule 16b-3 | 02/14/2025 |
11 | Cognition Therapeutics Announces Publication of Commercial Manuf | 02/20/2025 |
12 | Disposition of 2469 shares by Fletcher Aaron G.l. of Cognition Therapeutics at 1.92 subject to Rule 16b-3 | 02/21/2025 |
13 | Cognition Therapeutics Successfully Passes Pre-defined Futility Analysis of Phase 2 Study of ... | 02/26/2025 |
14 | Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD | 02/27/2025 |
| Begin Period Cash Flow | 41.6 M |
Cognition |
Cognition Therapeutics Relative Risk vs. Return Landscape
If you would invest 40.00 in Cognition Therapeutics on December 1, 2024 and sell it today you would earn a total of 5.00 from holding Cognition Therapeutics or generate 12.5% return on investment over 90 days. Cognition Therapeutics is currently generating 0.4281% in daily expected returns and assumes 7.0879% risk (volatility on return distribution) over the 90 days horizon. In different words, 63% of stocks are less volatile than Cognition, and 92% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cognition Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cognition Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cognition Therapeutics, and traders can use it to determine the average amount a Cognition Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0604
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CGTX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 7.09 actual daily | 63 63% of assets are less volatile |
Expected Return
| 0.43 actual daily | 8 92% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Cognition Therapeutics is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cognition Therapeutics by adding it to a well-diversified portfolio.
Cognition Therapeutics Fundamentals Growth
Cognition Stock prices reflect investors' perceptions of the future prospects and financial health of Cognition Therapeutics, and Cognition Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cognition Stock performance.
| Return On Equity | -1.58 | ||||
| Return On Asset | -1.1 | ||||
| Current Valuation | (2.39 M) | ||||
| Shares Outstanding | 41.55 M | ||||
| Price To Book | 1.31 X | ||||
| EBITDA | (25.51 M) | ||||
| Net Income | (25.79 M) | ||||
| Cash And Equivalents | 46.61 M | ||||
| Cash Per Share | 1.94 X | ||||
| Total Debt | 1.24 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 4.20 X | ||||
| Book Value Per Share | 0.35 X | ||||
| Cash Flow From Operations | (16.02 M) | ||||
| Earnings Per Share | (0.96) X | ||||
| Market Capitalization | 18.9 M | ||||
| Total Asset | 35.16 M | ||||
| Retained Earnings | (141.19 M) | ||||
| Working Capital | 24.05 M | ||||
About Cognition Therapeutics Performance
Evaluating Cognition Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Cognition Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cognition Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 7 K | 7.4 K | |
| Return On Tangible Assets | (0.66) | (0.69) | |
| Return On Capital Employed | (1.83) | (1.92) | |
| Return On Assets | (0.66) | (0.69) | |
| Return On Equity | (1.21) | (1.15) |
Things to note about Cognition Therapeutics performance evaluation
Checking the ongoing alerts about Cognition Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cognition Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cognition Therapeutics had very high historical volatility over the last 90 days | |
| Cognition Therapeutics has some characteristics of a very speculative penny stock | |
| Cognition Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (25.79 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Cognition Therapeutics currently holds about 46.61 M in cash with (16.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.94, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Cognition Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD |
- Analyzing Cognition Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cognition Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Cognition Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cognition Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cognition Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cognition Therapeutics' stock. These opinions can provide insight into Cognition Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Cognition Stock Analysis
When running Cognition Therapeutics' price analysis, check to measure Cognition Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cognition Therapeutics is operating at the current time. Most of Cognition Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cognition Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cognition Therapeutics' price. Additionally, you may evaluate how the addition of Cognition Therapeutics to your portfolios can decrease your overall portfolio volatility.